ZEMAIRA AUGMENTATION THERAPY

Augmentation therapy replaces what your body is missing.

Augmentation therapy

Zemaira is a natural Alpha-1 protein that is derived from human plasma. Zemaira replaces the protein that you are missing and raises alpha-1 antitrypsin levels in the blood. Since your body is unable to produce adequate levels of alpha-1 antitrypsin, augmentation (or replacement) therapy, such as Zemaira, is considered a lifelong therapy.

  • Zemaira is administered via intravenous infusion once per week.
  • It typically takes about 15 minutes to infuse Zemaira.
  • Depending on your insurance coverage, your personal preference, and what you and your healthcare provider decide is best for you, you may receive your infusions in either:
    • Your home.
    • An infusion center.

Goals of treatment

A focus of therapy for treating patients with emphysema due to severe alpha‑1 antitrypsin deficiency is augmentation therapy—also called replacement therapy. The basic goal of augmentation therapy is to increase the level of Alpha-1 protein in the lungs.2

Because Alpha-1 is caused by a deficiency of the protein alpha-1 antitrypsin—and potentially made worse by exposure to smoking, dust, and other irritants that cause inflammation—the following are some approaches to managing Alpha-16:

  • Decrease exposure to smoke, dust, and irritants that cause inflammation.2
  • Replace or augment the patient’s missing alpha-1 antitrypsin protein.2, 6
  • Incorporate bronchodilators or inhaled corticosteroids to provide symptom relief for patients with COPD-related Alpha-1.2

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2017 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR03-13-0022(3) 6/2015